PHARMIGENE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.4 TWD | +1.57% |
|
-0.51% | -6.28% |
| 2023 | Pharmigene, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| 2023 | Pharmigene, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| Sales 2021 | 129M 4M | Sales 2022 | 134M 4.13M | Capitalization | 863M 26.66M |
|---|---|---|---|---|---|
| Net income 2021 | -23M -711K | Net income 2022 | -42M -1.3M | EV / Sales 2021 | 5.56 x |
| Net cash position 2021 | 224M 6.93M | Net cash position 2022 | 186M 5.75M | EV / Sales 2022 | 5.06 x |
| P/E ratio 2021 |
-40.2
x | P/E ratio 2022 |
-20.2
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 49.29% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.57% | ||
| 1 week | -0.51% | ||
| Current month | +1.04% | ||
| 1 month | +1.04% | ||
| 3 months | +1.31% | ||
| 6 months | -15.65% | ||
| Current year | -6.28% |
1 week
19.00
19.80
1 month
19.0020.00
Current year
18.9021.10
1 year
18.9025.70
3 years
13.4027.10
5 years
13.4036.00
10 years
13.4036.00
| Managers | Title | Age | Since |
|---|---|---|---|
Fu Hui Chan
CEO | Chief Executive Officer | - | 19-11-03 |
Kuan Chih Chen
COO | Chief Operating Officer | - | 19-11-03 |
Wu Jung Hsieh
AUD | Comptroller/Controller/Auditor | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yi Hsiung Chen
BRD | Director/Board Member | - | 20-11-23 |
Chun Chi Chiang
BRD | Director/Board Member | - | - |
Fu Hui Chan
CEO | Chief Executive Officer | - | 19-11-03 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 19.4 | +1.57% | 37,600 |
| 24-04-29 | 19.1 | -1.55% | 7,000 |
| 24-04-26 | 19.4 | -1.02% | 23,000 |
| 24-04-25 | 19.6 | -.--% | 24,000 |
| 24-04-24 | 19.6 | -.--% | 35,200 |
End-of-day quote Taipei Exchange, April 29, 2024
More quotes
Pharmigene Inc is mainly engaged in drug gene diagnosis, functional medical testing services and agency sales of laboratory equipment and consumables. The Company mainly engages in field of genomics science, developing professional drug genetic diagnostic kits, testing technologies, and overall solutions for the research and development of drug genomics in precision medicine. The Company's molecular diagnostic products mainly include AutoEx16 automatic nucleic acid extractor, Clopidogrel drug effectiveness gene CYP2C19*2&*3 test kit, SGE 1502 test suite, SGE 3101 test suite, SGE 5701 test suite, Sega 5801 test kit, SGE B27 test kit, SGE whole blood calculation and extraction kit and others. Testing services include drug genetic testing projects, functional medical testing projects and personalized genetic testing. The Company mainly distributes its products in Taiwan market and other markets.
| 1st Jan change | Capi. | |
|---|---|---|
| -6.28% | 30.07M | |
| -18.16% | 11.03B | |
| +58.43% | 3.5B | |
| -31.31% | 2.23B | |
| -14.31% | 2.16B | |
| -26.61% | 1.54B | |
| +34.35% | 1.12B | |
| -3.28% | 737M | |
| -22.75% | 477M | |
| -40.20% | 411M |
- Stock Market
- Equities
- 7595 Stock
